期刊文献+

BCR⁃ABL融合基因检测试剂盒(荧光PCR法)的评价

Evaluation of BCR⁃ABL fusion gene detection kit by fluorescent PCR method
下载PDF
导出
摘要 目的评价不同公司的BCR⁃ABL融合基因检测试剂盒(荧光PCR法)的性能。方法提取BCR⁃ABL定量标准品WS1~WS4的RNA,分别加入BCR⁃ABL反应液和ABL反应液,然后使用荧光定量PCR仪进行检测。通过软件分析获得标准品的BCR⁃ABL融合基因检测结果。结果准确度标准品WS2和WS3的融合比例绝对偏差均不超过±0.5个对数数量级,检测限标准品WS4能检出BCR⁃ABL融合突变阳性,重复性标准品WS1和WS4的Ct值变异系数(CV,%)均<5.0%,WS1~WS4标准品的线性相关系数︱r︱不低于0.9800。结论BCR⁃ABL融合基因检测试剂盒(荧光PCR法)能够准确检出BCR⁃ABL定量标准品,符合断裂点簇集区⁃艾贝尔逊白血病病毒(BCR⁃ABL)融合基因检测试剂盒标准的准确度、检出限、重复性和线性要求。 Objective To evaluate the quality of BCR⁃ABL fusion gene testing kits based on fluorescent PCR method from different companies.Methods The RNA of the standard samples WS1~WS4 was extracted and added into BCR⁃ABL reaction solution and ABL reaction solution respectively,then detected by the fluorescence quantitative PCR instrument.The BCR⁃ABL fusion gene results of standards were obtained through software analysis.Results The absolute deviations of the fusion ratios of accuracy standards WS2 and WS3 are no more than±0.5 logarithmic order of magnitude.The detection limit standard WS4 can detect positive BCR⁃ABL fusion mutations.The Ct coefficient value of variation(CV%)of the repeatability standards WS1 and WS4 were less than 5.0%.The linear correlation coefficient|r|of WS1~WS4 standards was not less than 0.9800.Conclusion The BCR⁃ABL fusion gene detection kit(fluorescence PCR method)can accurately detect the BCR⁃ABL quantitative standard,which meets the accuracy of the breakpoint cluster region⁃Abelson leukemia virus(BCR⁃ABL)fusion gene detection kit standard,detection limit,repeatability and linearity requirements.
作者 张文新 曲守方 李丽莉 孙楠 黄传峰 黄杰 ZHANG Wenxin;QU Shoufang;LI Lili;SUN Nan;HUANG Chuanfeng;HUANG Jie(National Institutes for Food and Drug Control,Beijing,China,100050)
出处 《分子诊断与治疗杂志》 2023年第5期729-732,共4页 Journal of Molecular Diagnostics and Therapy
基金 国家药品监督管理局医疗器械推荐性行业标准制修订计划项目(I2022114⁃T⁃zjy)。
关键词 慢性髓性白血病 断裂点簇集区⁃艾贝尔逊白血病病毒融合基因 酪氨酸激酶抑制剂 国际标准化 准确度 Chronic myelogenous leukemia Breakpoint cluster region⁃Abelson leukemia virus fusion gene Tyrosine kinase inhibitors International scale Accuracy
  • 相关文献

参考文献4

二级参考文献23

  • 1李承文,薄丽津,秦爽,刘旭平,代芸,刘世和.连续R显带和荧光原位杂交技术在白血病诊断中的应用[J].中华检验医学杂志,2005,28(3):251-253. 被引量:3
  • 2Branford S,Hughes TP,Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable altemative to bone marrow cytogenetics[J].{H}British Journal of Haematology,1999,(3):587-599.
  • 3Hughes TP,Kaeda J,Branford S. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia[J].{H}New England Journal of Medicine,2003,(15):1423-1432.
  • 4Asnafi V,Rubio MT,Delabesse E. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia[J].{H}LEUKEMIA,2006,(5):793-799.
  • 5Zhang T,Grenier S,Nwachukwu B. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring:summary and recommendations[J].{H}Journal of Molecular Diagnostics,2007,(4):421-430.
  • 6Hughes T,Deininger M,Hochhaus A. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results[J].{H}Blood,2006,(1):28-37.
  • 7Branford S,Fletcher L,Cross NC. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials[J].{H}Blood,2008,(8):3330-3338.
  • 8Müller MC,Cross NC,Erben P. Harmonization of molecular monitoring of CML therapy in Europe[J].{H}LEUKEMIA,2009,(11):1957-1963.
  • 9Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia[J].{H}Best Pract Res Clin Rhemuatol,2009,(3):355-365.
  • 10Qin YZ,Jiang Q,Jiang H. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment,BCR-ABL(IS) or log reduction from the baseline level[J].{H}Leukemia Research,2013,(9):1035-1040.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部